A small Korean biotech called Rznomics just dropped Phase 1 interim data in hepatocellular carcinoma that is going to make people look up from their morning coffee at AACR.
The drug is RZ-001. It’s an RNA trans-splicing ribozyme.
Yeah, we’re all thinking it… “what the heck does that mean?”
Instead of targeting a protein, RZ-001 finds the oncogenic RNA transcript inside a tumor cell and literally swaps out the dangerous part for a therapeutic sequence. It edits the RNA mid-flight. The protein that gets made afterward either kills the cell or stops driving the cancer.
This is the first time that modality has generated serious clinical numbers in a solid tumor.
RZ-001 + atezolizumab + bevacizumab in HCC (interim Phase 1)
61.5%
~42%
23%
Source: AACR 2026 interim Phase 1 data
Context on why that matters. Atezolizumab plus bevacizumab is the current first-line standard of care in unresectable HCC. Its own ORR runs around 30% in the pivotal trials. Adding RZ-001 to that backbone roughly doubled it. The 23% complete response rate is the number that will trigger phone calls.
No Grade 3 or higher adverse events were attributed to RZ-001 in the interim analysis. For a new modality that is physically editing RNA inside tumor cells, that’s an unusually clean safety readout.
Zoom out and this is part of a larger shift. The Biotech Voyager has covered a steady drip of RNA-level therapeutics crossing into the clinic: Alltrna’s tRNA therapeutic, Tacit’s splice-switching work, AIRNA editing, Wayfinder’s small-molecule RNA binders. Each one attacks RNA from a different angle.
Rznomics is on the aggressive end. Trans-splicing doesn’t correct, silence, or modify a single base. It replaces a chunk of the transcript entirely with a therapeutic sequence carried by a viral vector. Which is why the complete responses are so interesting. The mechanism is designed to kill the cell outright, not tweak its biology.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you, contextualized and written directly to you, so you cut through the noise and immediately understand why it matters.
Patient numbers weren’t disclosed in the release, so the confidence intervals are wide. And HCC trials have a habit of looking great in early data and then regressing to the mean at scale.
But this is a new modality, in a cancer that kills almost everyone who gets it, posting numbers that competitive with the combination regimens big pharma is spending billions to improve. That’s a signal.
Keep an eye on where Rznomics goes next. Their platform spans oncology, rare disease, neurology, and ophthalmology. If trans-splicing works in HCC, these ribozymes have a lot of places to land.
